Objective To estimate clinical significance in the application of 23--valent peneurnococcal polysaccharide vaccine in COPD patients. Methods 100 subjects were divided into experimental group and control group randomly. 23-valent pneumococcal vaccines were injected to experimental group. They were observed the side effects for 1 week after vaccination. During 2 years observation, exacerbation frequency, pulmonary infection frequency,hospitalization, mortality, side effect were compared between two group. Results Exacerbation frequency, pulmonary infection frequency, hospitalization and mortality in experimental group were obviously less than control group.Most of side effects of vaccine were local reactions in inject site. They were relieved by local stupe or rest in 1-3 days.Conclusion 23-valent pneumococcal vaccines injection can reduce exacerbation frequency, pulmonary infection frequency, hospitalization, and mortality in stable COPD patients.%目的 评价23价肺炎球菌多糖疫苗(PPSV-23)接种在稳定期慢性阻塞性肺病(COPD)的作用.方法 将100例稳定期COPD患者随机分成干预组和对照组,干预组患者于接种后随访1周观察不良反应.注射疫苗2年内观察病情急性发作、肺部感染、住院次数、死亡率和不良反应,并与对照组进行对比.结果 干预组急性发作次数、肺部感染、住院次数、病死率均低于对照组.接种后不良反应多为局部反应,经热敷或休息1～3d可缓解.结论 PPSV-23可以减少稳定期COPD患者急性发作率、肺部感染率、住院率、死亡率.
展开▼
